Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41


A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers.

Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB.

Clin Proteomics. 2010 Dec;6(4):129-51. doi: 10.1007/s12014-010-9055-y.


Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.

Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS.

Future Med Chem. 2009 Sep;1(6):1153-71. doi: 10.4155/fmc.09.89.


Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.

Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K.

Oncogene. 2011 Jun 16;30(24):2730-40. doi: 10.1038/onc.2010.640. Epub 2011 Jan 31.


18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.

McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC.

Clin Cancer Res. 2011 May 15;17(10):3332-40. doi: 10.1158/1078-0432.CCR-10-2274. Epub 2011 Jan 21.


Growth hormone, the insulin-like growth factor axis, insulin and cancer risk.

Clayton PE, Banerjee I, Murray PG, Renehan AG.

Nat Rev Endocrinol. 2011 Jan;7(1):11-24. doi: 10.1038/nrendo.2010.171. Epub 2010 Oct 19. Review.


Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.

Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR.

Mol Cancer Ther. 2010 Oct;9(10):2652-64. doi: 10.1158/1535-7163.MCT-10-0318. Epub 2010 Oct 5.


Genomic index of sensitivity to endocrine therapy for breast cancer.

Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2010 Sep 20;28(27):4111-9. doi: 10.1200/JCO.2010.28.4273. Epub 2010 Aug 9.


Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL.

J Clin Invest. 2010 Jul;120(7):2406-13. doi: 10.1172/JCI41680. Epub 2010 Jun 7.


Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Ulanet DB, Ludwig DL, Kahn CR, Hanahan D.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8. doi: 10.1073/pnas.0914076107. Epub 2010 May 10.


Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, Kurshan N, Mejia W, Santopietro S, Yakar S, Wood TL, LeRoith D.

Cancer Res. 2010 Jan 15;70(2):741-51. doi: 10.1158/0008-5472.CAN-09-2141. Epub 2010 Jan 12.


Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.

Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, Lewis Phillips GD, Luis E, Cavet G, Hu X, Amler LC, Lackner MR.

Mol Cancer Ther. 2009 Aug;8(8):2110-21. doi: 10.1158/1535-7163.MCT-09-0381. Epub 2009 Aug 11.


Biomarker discovery: identification of a growth factor gene signature.

Loboda A, Nebozhyn M, Cheng C, Vessey R, Huang P, Dai H, Watters JW.

Clin Pharmacol Ther. 2009 Jul;86(1):92-6. doi: 10.1038/clpt.2009.48. Epub 2009 Apr 22.


Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE.

Cancer Res. 2008 Dec 15;68(24):10238-46. doi: 10.1158/0008-5472.CAN-08-2755.


IGF-1 receptor inhibitors in clinical trials--early lessons.

Weroha SJ, Haluska P.

J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):471-83. doi: 10.1007/s10911-008-9104-6. Epub 2008 Nov 21. Review.


IGF and insulin receptor signaling in breast cancer.

Belfiore A, Frasca F.

J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):381-406. doi: 10.1007/s10911-008-9099-z. Epub 2008 Nov 19.


Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.

Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV.

J Clin Oncol. 2008 Sep 1;26(25):4078-85. doi: 10.1200/JCO.2007.13.4429.


Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.

Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C.

BMC Genomics. 2008 May 22;9:239. doi: 10.1186/1471-2164-9-239.


Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R.

Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707.


Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A.

Cancer Cell. 2008 Feb;13(2):91-104. doi: 10.1016/j.ccr.2008.01.001.


Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M.

Lancet Oncol. 2008 Jan;9(1):45-53.


Supplemental Content

Support Center